Literature DB >> 36138311

Defining Facility Volume Threshold for Optimization of Short- and Long-Term Outcomes in Patients Undergoing Resection of Perihilar Cholangiocarcinoma.

Mohamedraed Elshami1, Jonathan J Hue1, Fasih Ali Ahmed1, Hanna Kakish1, Richard S Hoehn1, Luke D Rothermel1, Jeffrey M Hardacre1, John B Ammori1, Jordan M Winter1, Lee M Ocuin2.   

Abstract

BACKGROUND: We determined the minimum threshold (Tmin) of annual facility case volume to optimize outcomes for patients with resected perihilar cholangiocarcinoma.
METHODS: We identified patients with localized perihilar cholangiocarcinoma who underwent resection within the National Cancer Database (2010-2017). We used marginal structural logistic regression models to estimate the average treatment effect of receiving care in facilities meeting/exceeding Tmin on 90-day mortality and other postoperative outcomes.
RESULTS: A total of 2471 patients underwent resection for perihilar cholangiocarcinoma at 471 facilities. There was no effect of total hepatopancreatobiliary, surgical hepatopancreatobiliary, total hepatobiliary, surgical hepatobiliary, or total perihilar cholangiocarcinoma case volume on 90-day mortality. A Tmin of seven perihilar cholangiocarcinoma resections/year resulted in lower odds of 90-day mortality (IP-weighted OR = 0.49, 95% CI: 0.66-0.87). A total of two facilities met the Tmin. Patients receiving treatment at Tmin facilities had lower odds of length of stay ≥ 7 days (IP-weighted OR = 0.85, 95% CI: 0.75-0.97) and positive surgical resection margins (IP-weighted OR = 0.40, 95% CI: 0.47-0.55). Additionally, undergoing surgery at Tmin facilities resulted in higher (≥ 4 nodes) lymph node yields (IP-weighted OR = 1.94, 95% CI: 1.21-3.11) but no change in the odds of nodal positivity. There was no effect of undergoing surgery at Tmin facilities on 30-day mortality or re-admission.
CONCLUSIONS: Resection of perihilar cholangiocarcinoma is infrequently performed at a high number of facilities. A Tmin of ≥ 7 resections/year resulted in lower 90-day mortality and improved postoperative outcomes. Our data suggest that regionalization of care for patients with perihilar cholangiocarcinoma could potentially improve outcomes in the USA.
© 2022. The Society for Surgery of the Alimentary Tract.

Entities:  

Keywords:  90-day mortality; Facility volume; Perihilar cholangiocarcinoma; Survival; Volume-outcomes relationship

Year:  2022        PMID: 36138311     DOI: 10.1007/s11605-022-05465-z

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.267


  42 in total

1.  The impact of portal vein resection on outcomes for hilar cholangiocarcinoma: a multi-institutional analysis of 305 cases.

Authors:  Mechteld C de Jong; Hugo Marques; Bryan M Clary; Todd W Bauer; J Wallis Marsh; Dario Ribero; Pietro Majno; Ioannis Hatzaras; Dustin M Walters; Andrew S Barbas; Raquel Mega; Richard D Schulick; Michael A Choti; David A Geller; Eduardo Barroso; Gilles Mentha; Lorenzo Capussotti; Timothy M Pawlik
Journal:  Cancer       Date:  2012-03-13       Impact factor: 6.860

2.  Improvement in perioperative and long-term outcome after surgical treatment of hilar cholangiocarcinoma: results of an Italian multicenter analysis of 440 patients.

Authors:  Gennaro Nuzzo; Felice Giuliante; Francesco Ardito; Ivo Giovannini; Luca Aldrighetti; Giulio Belli; Fabrizio Bresadola; Fulvio Calise; Raffaele Dalla Valle; Davide F D'Amico; Leandro Gennari; Stefano M Giulini; Alfredo Guglielmi; Elio Jovine; Riccardo Pellicci; Heinrich Pernthaler; Antonio D Pinna; Stefano Puleo; Guido Torzilli; Lorenzo Capussotti; Umberto Cillo; Giorgio Ercolani; Massimo Ferrucci; Laura Mastrangelo; Nazario Portolani; Carlo Pulitanò; Dario Ribero; Andrea Ruzzenente; Vincenzo Scuderi; Bruno Federico
Journal:  Arch Surg       Date:  2012-01

3.  The concept of perihilar cholangiocarcinoma is valid.

Authors:  T Ebata; J Kamiya; H Nishio; T Nagasaka; Y Nimura; M Nagino
Journal:  Br J Surg       Date:  2009-08       Impact factor: 6.939

4.  Reassessing the role of surgery in the elderly or chronically sick with proximal extrahepatic cholangiocarcinoma.

Authors:  Jonathan J Hue; Kavin Sugumar; Sarah C Markt; Amr Mohamed; J Eva Selfridge; David Bajor; Luke D Rothermel; Jeffrey M Hardacre; John B Ammori; Jordan M Winter; Lee M Ocuin
Journal:  Surgery       Date:  2020-10-18       Impact factor: 3.982

5.  Multicentre European study of preoperative biliary drainage for hilar cholangiocarcinoma.

Authors:  O Farges; J M Regimbeau; D Fuks; Y P Le Treut; D Cherqui; P Bachellier; J Y Mabrut; M Adham; F R Pruvot; J F Gigot
Journal:  Br J Surg       Date:  2012-11-02       Impact factor: 6.939

Review 6.  Hilar Cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system.

Authors:  E C Burke; W R Jarnagin; S N Hochwald; P W Pisters; Y Fong; L H Blumgart
Journal:  Ann Surg       Date:  1998-09       Impact factor: 12.969

Review 7.  Hilar cholangiocarcinoma: diagnosis, treatment options, and management.

Authors:  Kevin C Soares; Ihab Kamel; David P Cosgrove; Joseph M Herman; Timothy M Pawlik
Journal:  Hepatobiliary Surg Nutr       Date:  2014-02       Impact factor: 7.293

Review 8.  Surgery for cholangiocarcinoma.

Authors:  Umberto Cillo; Constantino Fondevila; Matteo Donadon; Enrico Gringeri; Federico Mocchegiani; Hans J Schlitt; Jan N M Ijzermans; Marco Vivarelli; Krzysztof Zieniewicz; Steven W M Olde Damink; Bas Groot Koerkamp
Journal:  Liver Int       Date:  2019-05       Impact factor: 5.828

9.  Perihilar Cholangiocarcinoma - Novel Benchmark Values for Surgical and Oncological Outcomes From 24 Expert Centers.

Authors:  Matteo Mueller; Eva Breuer; Takashi Mizuno; Fabian Bartsch; Francesca Ratti; Christian Benzing; Noémie Ammar-Khodja; Teiichi Sugiura; Tsukasa Takayashiki; Amelia Hessheimer; Hyung Sun Kim; Andrea Ruzzenente; Keun Soo Ahn; Tiffany Wong; Jan Bednarsch; Mizelle D'Silva; Bas Groot Koerkamp; Heithem Jeddou; Victor López-López; Charles de Ponthaud; Jennifer A Yonkus; Warsan Ismail; Lynn E Nooijen; Camila Hidalgo-Salinas; Elissaios Kontis; Kim C Wagner; Ganesh Gunasekaran; Ryota Higuchi; Ana Gleisner; Chaya Shwaartz; Gonzalo Sapisochin; Richard D Schulick; Masakazu Yamamoto; Takehiro Noji; Satoshi Hirano; Myron Schwartz; Karl J Oldhafer; Andreas Prachalias; Giuseppe K Fusai; Joris I Erdmann; Pål-Dag Line; Rory L Smoot; Olivier Soubrane; Ricardo Robles-Campos; Karim Boudjema; Wojciech G Polak; Ho-Seong Han; Ulf P Neumann; Chung-Mau Lo; Koo Jeong Kang; Alfredo Guglielmi; Joon Seong Park; Constantino Fondevila; Masayuki Ohtsuka; Katsuhiko Uesaka; René Adam; Johann Pratschke; Luca Aldrighetti; Michelle L De Oliveira; Gregory J Gores; Hauke Lang; Masato Nagino; Pierre-Alain Clavien
Journal:  Ann Surg       Date:  2021-11-01       Impact factor: 12.969

10.  Surgery for Bismuth-Corlette Type 4 Perihilar Cholangiocarcinoma: Results from a Western Multicenter Collaborative Group.

Authors:  Andrea Ruzzenente; Fabio Bagante; Pim B Olthof; Luca Aldrighetti; Ruslan Alikhanov; Matteo Cescon; Bas Groot Koerkamp; William R Jarnagin; Silvio Nadalin; Johann Pratschke; Moritz Schmelzle; Ernesto Sparrelid; Hauke Lang; Calogero Iacono; Thomas M van Gulik; Alfredo Guglielmi
Journal:  Ann Surg Oncol       Date:  2021-05-06       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.